AI‑driven discovery produced two notable developments: Insilico Medicine reported an AI‑designed PROTAC degrader targeting PKMYT1 with preclinical efficacy across biomarker‑selected models, and PsiThera, a Roivant spinout, closed $47.5 million to pursue AI‑designed oral inhibitors aimed at tumor necrosis factor signaling. Insilico’s work, published in Nature Communications, used generative chemistry to produce a bifunctional degrader showing activity in CCNE1‑amplified and FBXW7‑mutant models. PsiThera will apply its platform to find small molecules that emulate biologic efficacy against TNF, aiming to deliver oral alternatives to injectable biologics. Both programs highlight the industry’s growing confidence that generative AI and physics‑aware models can produce candidates advancing into preclinical validation and IND‑enabling work. Translational hurdles remain — pharmacokinetics, safety and manufacturability — but these announcements reinforce investor interest and industry adoption of AI as an accelerated route to novel modalities.